DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Ongoing pregnancies after vitrification of human oocytes using a combined solution of ethylene glycol and dimethyl sulfoxide.

Author(s): Selman H, Angelini A, Barnocchi N, Brusco GF, Pacchiarotti A, Aragona C

Affiliation(s): Centro Sterilita e Fecondazione Assistita Policlinico di Perugia, University of Perugia, Perugia, Italy. selmanha@yahoo.com

Publication date & source: 2006-10, Fertil Steril., 86(4):997-1000. Epub 2006 Sep 11.

OBJECTIVE: To evaluate a vitrification solution using a mixture of two cryprotectant agents, dimethyl sulfoxide and ethylyne glycol plus sucrose, on the survival of human oocytes. DESIGN: Clinical study of cryopreservation of human metaphase II (MII) oocytes by vitrification. SETTING: University-affiliated IVF center. PATIENT(S): Infertile couples who agreed to have their surplus oocytes vitrified during the fresh IVF cycle. INTERVENTION(S): Vitrification of surplus oocytes subsequently used in the next cycle and assisted fertilization by intracytoplasmic sperm injection. MAIN OUTCOME MEASURE(S): Morphologic survival and normal fertilization, embryo development, and clinical outcome. RESULT(S): A total of 53 surplus MII oocytes from 6 patients were vitrified, of which 24 were thawed, resulting in 18 which survived morphologically (75%). Following insemination, 14 of the 18 surviving eggs were fertilized (77.7%). All zygotes developed into viable embryos that were replaced into each patient's uterus, resulting in two healthy pregnancies: one singleton and one twin. The pregnancies were ongoing. CONCLUSION(S): Cryopreservation of human MII oocytes by vitrification appears to be a promising procedure, though to assure optimal effectiveness of this protocol further studies should be undertaken.

Page last updated: 2007-02-13

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017